
Icade's H1 update: EUR 402m sale on Champs-Élysées, EUR 75m Portuguese exit, and full ownership of EQHO tower. The disposal plan accelerates.
Icade advanced its asset disposal program in the first half. It sold a building on the Champs-Élysées for EUR 402 million and signed an agreement to exit its Portuguese healthcare real estate exposure. The company also regained full ownership of its La Défense tower, EQHO.
The sale of the Marignan building on the Champs-Élysées was completed in the period, CEO Nicolas Joly said on the company's half-year results call. The EUR 402 million price reflects the value of prime Paris office assets, Joly noted.
Separately, Icade signed an agreement to sell its Portuguese healthcare portfolio. The exposure for Icade is around EUR 75 million, Joly said. The disposal is part of a broader strategy to reduce the company's international healthcare footprint and focus on core French assets.
On EQHO, Joly said:
Last week, we announced the acquisition of the remaining 49% minority stake in the tower, allowing us to regain full ownership of this landmark asset in La Défense.
Regaining full control gives Icade flexibility to pursue future development or a potential sale of the tower without minority partner constraints, the CEO added.
The half-year call featured CFO Bruno Valentin presenting financial details, though the excerpts available did not include specific revenue, net income, or portfolio valuation figures. Icade's disposal execution and the EQHO buyback are the headline strategic moves from the first six months.
The Portuguese sale remains subject to customary closing conditions. Icade did not provide a timeline for finalization. The company's next major catalyst will be the completion of that disposal and the deployment of proceeds into its development pipeline or further debt reduction.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.